Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
Int J Clin Pract ; 2022: 7726126, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35685489

RESUMEN

Background: Previous evidence suggests a link between diet quality and breast cancer (BrCa); however, the link between the Lifelines Diet Score (LLDS)-a fully food-based score that uses the 2015 Dutch Dietary Guidelines-and risk of BrCa has not yet been evaluated. Therefore, the aim of this study was to observe the relationship between adherence to an LLDS and risk of BrCa in Iranian adults. Methods: In the hospital-based case-control study, 253 patients with BrCa and 267 non-BrCa controls were enrolled. Individual's food consumption was recorded to calculate LLDS using a semiquantitative food frequency questionnaire. In adjusted models, the association between the inflammatory potential of the diet and the risk of BrCa was estimated by using binary logistic regression. Results: Compared with control individuals, BrCa patients significantly had higher waist circumference (WC), first pregnancy age, abortion history, and number of children. In addition, the mean intake of vitamin D supplements and anti-inflammatory drugs in the case group was significantly lower than the control group. Furthermore, after adjusted potential confounders, individuals in the highest vs. lowest quartiles of LLDS showed statistically significant lower risk of BrCa in overall population (OR: 0.21; 95% CI: 0.11-0.43; P trend <0.001), premenopausal (OR: 0.26; 95% CI: 0.10-0.68; P trend = 0.003), and post-menopausal women (OR: 0.20; 95% CI: 0.06-0.60; P trend = 0.015). Conclusion: Findings of this study reflected that higher LLDS decreased risk of BrCa, but need further investigation in later studies.


Asunto(s)
Neoplasias de la Mama , Adulto , Neoplasias de la Mama/epidemiología , Neoplasias de la Mama/prevención & control , Estudios de Casos y Controles , Niño , Dieta , Femenino , Alimentos , Humanos , Irán/epidemiología , Factores de Riesgo
2.
Pain Manag Nurs ; 23(4): 458-466, 2022 08.
Artículo en Inglés | MEDLINE | ID: mdl-35279360

RESUMEN

OBJECTIVES: Despite the widespread use of complementary and alternative medicine by patients and physicians alike, there is no accurate evidence regarding the effects of vitamin D supplementation on treatment-induced pain in cancer patients. Thus, the aim of this systematic review of randomized controlled trials (RCTs) was to evaluate the impact of vitamin D administration on therapy-related pain in subjects diagnosed with malignant disorders. REVIEW ANALYSIS METHODS: We searched the Web of Science, Scopus, PubMed/Medline, Embase, and Google Scholar databases up to October 2020 to identify published RCTs that investigated the use of vitamin D in the management of treatment-induced pain in individuals with cancer. RESULTS: Nine RCTs were detected. The median duration of the intervention was of 24 weeks (range 12-52 weeks) and dose of vitamin D employed was 2000-50000 IU of vitamin D3 weekly orally each day. Six RCTs reported a significant reduction in pain, whereas three did not detect a notable decrease of this variable. Of the six studies that reported an alleviation of pain, an RCT which recruited 60 participants and lasted for 24 weeks consisted of supplementation with high doses of vitamin D2 weekly for 8 weeks in women receiving anastrozole as adjuvant therapy, then supplementation with vitamin D2 monthly for 4 months, effectively alleviated the aromatase inhibitor-associated musculoskeletal syndrome (AIMSS). The results of the same RCT also suggested a beneficial effect of vitamin D on musculoskeletal pain. CONCLUSIONS: Our results suggest that the supplementation with high doses of vitamin D in cancer patients with low serum levels of vitamin D, can be effective in reducing treatment-related pain.


Asunto(s)
Dolor en Cáncer , Dolor Musculoesquelético , Neoplasias , Dolor en Cáncer/tratamiento farmacológico , Suplementos Dietéticos , Ergocalciferoles/efectos adversos , Femenino , Humanos , Dolor Musculoesquelético/tratamiento farmacológico , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológico , Vitamina D/uso terapéutico
3.
Nutr Neurosci ; 25(11): 2421-2430, 2022 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-34328397

RESUMEN

BACKGROUND: Although there is ample evidence for the effect of omega-3 supplementation on seizure frequency in individuals with epilepsy, the results are inconsistent. Therefore, we conducted this systematic review and meta-analysis to elucidate the potential effect of omega-3 supplementation in the adult and pediatric population. METHODS: Clinical trials articles were searched in electronic databases (Web of Science, Scopus, PubMed/Medline, Embase, and Google Scholar database up to October 2020). No language limitation was imposed in the literature search. Moreover, gray literature search was done via searching the references of identified review papers to find more potentially relevant articles. RESULTS: In order, the duration of the intervention and dosage of omega-3 fatty acid supplement of the included studies ranged from 12 to 42 weeks and 1000-2880 mg/day. Pooled results from the random-effects model indicated that seizure frequency following supplementation of omega-3 fatty acid decreased significantly (WMD: -6.15, 95% CI: -7.78, -4.53, P < 0.001). Furthermore, the results of the subgroup analysis revealed that seizure frequency was more alleviated in studies that used a daily dose of 1500 mg or less of omega-3 fatty acids as well as studies that had an intervention duration of more than 16 weeks. More importantly, our findings also showed that the effect of omega-3 intervention was greater in adults than in children with epilepsy. CONCLUSION: The current meta-analysis on available trials suggested that omega-3 supplementation resulted in beneficial effects on seizure frequency in adult and children with epilepsy.


Asunto(s)
Epilepsia , Ácidos Grasos Omega-3 , Adulto , Niño , Humanos , Suplementos Dietéticos , Epilepsia/tratamiento farmacológico , Convulsiones/prevención & control , Convulsiones/tratamiento farmacológico
4.
Clin Nutr ; 40(2): 394-403, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-32698957

RESUMEN

BACKGROUND: The investigation was designed to assess the effects of synbiotic supplementation on glycemic profile, insulin-like growth factor-1 (IGF-1) and sex hormones in overweight and obese postmenopausal breast cancer survivors (BCSs) who had hormone-receptor-positive breast cancer. METHODS: This randomized, triple-blind, placebo-controlled trial was conducted on 76 overweight and obese BCSs aged 57.43 (5.82) years. All participants were given a specified low calorie diet and were randomly assigned into two groups to intake 109 CFU/day of synbiotic supplement (n = 38) or placebo (n = 38) for 8 weeks. Body composition, physical activity, glycemic profile, IGF-1, estradiol, testosterone and dehydroepiandrosterone sulfate (DHEA-S) were measured at baseline and after 8 weeks. RESULTS: A significant reduction in serum insulin (median change (Q1, Q3) from baseline of -1.05 (-2.36, 0.32) µIU/mL; P = 0.006) and insulin resistance (HOMA-IR) (mean change (SD) from baseline of -4.0 (0.9); P = 0.007) were seen over the 8 weeks in the synbiotic group. However, no significant changes were observed in serum insulin, fasting plasma glucose, HbA1c, HOMA-IR, IGF-1, estradiol, testosterone, DHEA-S and sex hormone binding globulin between-groups at the end of the intervention. CONCLUSIONS: Overall, as the 8-week synbiotic consumption compared with placebo had insignificant-reducing effects on glycemic profile, IGF-1 and sex hormones among overweight and obese postmenopausal BCSs, synbiotics may exert considerable beneficial consequences, which need to be further assessed in future clinical trials. TRIAL REGISTRATION: IRCT, IRCT2015090223861N1. Registered 02 February 2017, http://www.irct.ir: IRCT2015090223861N1.


Asunto(s)
Neoplasias de la Mama/sangre , Dieta Reductora/métodos , Obesidad/dietoterapia , Sobrepeso/dietoterapia , Simbióticos/administración & dosificación , Anciano , Glucemia/metabolismo , Neoplasias de la Mama/complicaciones , Supervivientes de Cáncer , Sulfato de Deshidroepiandrosterona/sangre , Estradiol/sangre , Femenino , Hemoglobina Glucada/metabolismo , Humanos , Insulina/sangre , Resistencia a la Insulina , Factor I del Crecimiento Similar a la Insulina/metabolismo , Persona de Mediana Edad , Obesidad/complicaciones , Obesidad/microbiología , Sobrepeso/complicaciones , Sobrepeso/microbiología , Proyectos de Investigación , Globulina de Unión a Hormona Sexual/metabolismo , Testosterona/sangre , Resultado del Tratamiento
5.
Artículo en Inglés | MEDLINE | ID: mdl-33224249

RESUMEN

BACKGROUND AND AIMS: Improved vitamin D levels can have a favorable effect on some metabolic variables. The objective of the current study was to determine the effects of vitamin D supplementation during a weight-loss intervention on the levels of omentin-1, spexin, lipid profiles, and inflammatory factors in obese and overweight participants. METHODS AND MATERIALS: In this double-blind placebo-controlled randomized clinical trial, 70 overweight and obese participants with vitamin D deficiency (25(OH)D ≤ 20 nmol/L) were assigned into the intervention (a daily dose of 2,000 IU vitamin D + low-calorie diet) and placebo (placebo + low-calorie diet) groups for 8 weeks. Anthropometric parameters, serum levels of 25-hydroxy vitamin D (25(OH)D), lipid profiles, omentin-1 and spexin levels, high-sensitivity C-reactive protein (hs-CRP), and soluble intercellular adhesion molecule-1 (sICAM-1) concentrations were assessed before and after the intervention. RESULTS: Vitamin D supplementation after the intervention led to a significant decrease in triglycerides (TG) (P = 0.02), very-low-density lipoprotein-cholesterol (VLDL-C) (P = 0.02), and hs-CRP (P = 0.03) concentrations and a significant increase in the serum vitamin D level (P < 0.001). Furthermore, after adjusting for baseline values, age, and baseline BMI, the levels of serum high-density lipoprotein-cholesterol (HDL-C) (P = 0.01) increased significantly, and a significant reduction was observed in the concentration of sICAM-1 (P = 0.01) in the intervention group. However, we did not find any significant difference in serum omentin-1 and spexin concentrations between the groups after intervention. CONCLUSIONS: Vitamin D supplementation along with a low-calorie diet (LCD) program for 8 weeks significantly decreased the inflammatory markers in obese individuals, while it did not alter serum omentin-1 and spexin concentrations.

6.
Nutr Cancer ; 72(1): 62-73, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31135225

RESUMEN

Background and Aims: Synbiotics found to be beneficial in breast cancer survivors (BCSs) through its antioxidant properties. The aim of this study was to assess the effects of synbiotic supplementation on edema volume and some oxidative markers among obese and overweight patients with BCRL.Method: This randomized double-blind, placebo-controlled trial was conducted on 88 overweight and obese BCSs aged 18-65 years. All the subjects were given a specified low-calorie diet (LCD) and were randomly assigned into two groups to intake 109 CFU/day synbiotic supplement (n = 44) or placebo (n = 44) for 10 wk. Edema volume and serum total antioxidant capacity (TAC), malondialdehyde (MDA), glutathione peroxidase (GPx), and superoxide dismutase (SOD) concentration were measured at baseline and after the 10-wk intervention.Results: Ten-wk supplementation with synbiotics leads to a significant reduction in serum MDA levels (P = 0.001) and an increase in serum SOD concentration (P = 0.007) compared to placebo. No significant changes were observed in serum GPx, TAC, and edema volume between groups.Conclusion: Our findings reveal that 10-wk synbiotic supplementation along with a LCD program-reduced serum MDA levels and elevate the activity of SOD in overweight and obese patients with BCRL. However, its effect on serum GPx, TAC, and edema volume was not significant.


Asunto(s)
Antioxidantes/metabolismo , Brazo/fisiología , Neoplasias de la Mama/complicaciones , Supervivientes de Cáncer/estadística & datos numéricos , Linfedema/dietoterapia , Estrés Oxidativo/fisiología , Simbióticos/administración & dosificación , Adolescente , Adulto , Biomarcadores/sangre , Neoplasias de la Mama/patología , Proteína C-Reactiva/metabolismo , Restricción Calórica/normas , Suplementos Dietéticos , Método Doble Ciego , Femenino , Humanos , Linfedema/etiología , Linfedema/patología , Malondialdehído/sangre , Persona de Mediana Edad , Superóxido Dismutasa-1/sangre , Adulto Joven
7.
Phytother Res ; 33(8): 1957-1965, 2019 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31225678

RESUMEN

Breast cancer is the most commonly diagnosed cancer and is the leading cause of mortality due to all types of cancers among the female population worldwide. Results of clinical trials investigating the effect of ginger on chemotherapy-induced nausea and vomiting (CINV) in breast cancer patients are inconsistent. This study was aimed at obtaining a comprehensive overview of the current evidence regarding the effectiveness of ginger as an antiemetic modality for controlling CINV in breast cancer patients. All published randomized controlled trials in English were systematically searched on Google Scholar, PubMed, Scopus, and Cochrane search databases up to June 2018. The outcome variable of interest was severity and the frequency of nausea and vomiting in patients. A total of 50 studies were found through search databases. After excluding duplicates, the 42 remaining studies were screened, and finally, nine trials were included, which were published between 2012 and 2017. Two studies have examined the effect of ginger on the frequency of nausea, five studies on the frequency of vomiting, seven studies on the severity of nausea, and three studies on severity of vomiting. A study evaluated the effectiveness of ginger in improving dietary intake in CINV. Our investigation suggests that ginger may reduce nausea in the acute phase of chemotherapy in patients with breast cancer. The effect of ginger on nausea and vomiting in other conditions requires more high-quality clinical trials.


Asunto(s)
Neoplasias de la Mama/complicaciones , Náusea/dietoterapia , Vómitos/dietoterapia , Zingiber officinale/química , Adulto , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Femenino , Humanos , Persona de Mediana Edad , Náusea/inducido químicamente , Ensayos Clínicos Controlados Aleatorios como Asunto , Vómitos/inducido químicamente
8.
Nutr Cancer ; 71(6): 922-930, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30945949

RESUMEN

Gastrointestinal (GI) side effects caused by chemotherapy in women with breast cancer are common but poorly understood which might be controlled by nutritional intervention. Thus, the major aim of this study was to assess the effect of dietary intervention along with nutritional education on reducing these side effects. The present study is a single-center, single-controlled, and randomized trial. A total of 150 patients with breast cancer undergoing chemotherapy were randomly assigned into intervention group to receive dietary intervention and nutritional education (n = 73) or control group (n = 67) for 10 weeks, after their three sessions of chemotherapy. The primary endpoint was the GI symptoms after each session of chemotherapy that were measured by a designed questionnaire based on ROMIII questionnaire. The severity of GI side effects in the dietary intervention along with nutritional education was decreased significantly in the third session of chemotherapy compared to the first session, which include reflux disorder (P = 0.05), anorexia (P < 0.001), nausea (P = 0.002), constipation (P < 0.001), and diarrhea (P < 0.001). Moreover, significant reductions were observed in the severity of GI side effects in the intervention group compared to control group after the third session (P < 0.001). After adjusting the analysis for baseline values including age, job, education level, weight, and body mass index, significant changes were observed for GI side effects in the intervention group compared to the control group (P < 0.001). This study showed beneficial effects of individualized dietary intervention along with nutritional education on reducing diarrhea, constipation, vomiting, and nausea in women with breast cancer during the chemotherapy.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/dietoterapia , Neoplasias de la Mama/tratamiento farmacológico , Consejo/métodos , Enfermedades Gastrointestinales/dietoterapia , Terapia Nutricional/métodos , Adulto , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Femenino , Enfermedades Gastrointestinales/inducido químicamente , Humanos , Persona de Mediana Edad
9.
J Matern Fetal Neonatal Med ; 31(9): 1128-1136, 2018 May.
Artículo en Inglés | MEDLINE | ID: mdl-28326881

RESUMEN

OBJECTIVE: This study was designed to evaluate the effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes among subjects with gestational diabetes (GDM). METHODS: This randomized, double-blind, placebo-controlled clinical trial was done among 60 subjects with GDM who were not on oral hypoglycemic agents. Patients were randomly allocated to intake either probiotic capsule containing Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium bifidum (2 × 109 CFU/g each) (n = 30) or placebo (n = 30) for six weeks. RESULTS: Compared with the placebo, probiotic supplementation resulted in significant decreases in fasting plasma glucose (FPG) (-5.3 ± 6.7 vs. +0.03 ± 9.0 mg/dL, p = .01), serum high-sensitivity C-reactive protein (hs-CRP) (-2.2 ± 2.7 vs. +0.5 ± 2.4 µg/mL, p < .001), plasma malondialdehyde (MDA) concentrations (-0.1 ± 0.8 vs. +0.5 ± 1.5 µmol/L, p = .03) and MDA/TAC ratio (-0.0003 ± 0.0008 vs. +0.0009 ± 0.002, p = .004), and a significant increase in total antioxidant capacity (TAC) levels (+65.4 ± 103.3 vs. -37.2 ± 143.7 mmol/L, p = .002). Probiotic supplementation did not affect pregnancy outcomes. CONCLUSIONS: Overall, probiotic supplementation among women with GDM for six weeks had beneficial effects on FPG, serum hs-CRP, plasma TAC, MDA and oxidative stress index, but did not affect pregnancy outcomes.


Asunto(s)
Biomarcadores/sangre , Diabetes Gestacional/sangre , Inflamación/sangre , Estrés Oxidativo/fisiología , Resultado del Embarazo , Probióticos/administración & dosificación , Adulto , Glucemia/análisis , Proteína C-Reactiva/análisis , Suplementos Dietéticos , Método Doble Ciego , Femenino , Humanos , Malondialdehído/sangre , Placebos , Embarazo
10.
EXCLI J ; 16: 278-290, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28507473

RESUMEN

Non-alcoholic fatty liver disease (NAFLD) has been suggested to be well correlated with altered blood pressure. This study was conducted to determine the effects of symbiotic and vitamin E supplementation on blood pressure and inflammatory indices of patients with NAFLD. This randomized, double-blind, placebo-controlled trial was performed among 60 NAFLD patients aged 25 to 64 years old. Participants were randomly divided into four groups to receive a 400 IU alpha-tocopherol and 2 × 108 CFU/g symbiotic supplement for 8 weeks. The anthropometric parameters, systolic blood pressure (SBP) and diastolic blood pressure (DBP), serum malondialdehyde (MDA), nitric oxide (NO) and tumor necrosis factor α (TNFα) were assessed at baseline and after 8 weeks of intervention. After 8 weeks of intervention, combined symbiotic and alpha-tocopherol, symbiotic and alpha-tocopherol alone administration, compared with the placebo, resulted in significant decreases in SBP (-17.07±2.1, -16.07±3.56, -1.73±2.25 and -1.55±3.01 mmHg, P=0.01), serum MDA (-1.19±0.5, -0.12±0.65, 0.14 ± 0.64 and 0.16±0.34 nmol/mL, P<0.001), serum TNFα (-15.62±13.93, -9.24±7.12, -11.44 ± 15.47 and 3.01±1.71 pg/ml, P<0.001) concentrations. A significant decrease in serum AST (-11.36±4.52, -7.43±8.58, -5.93±6.61 and 2.5±5.75 µmol/L, P <0.001), ALT (-12.79±3.65, -3.66±6.81, -6.54±7.66 and 4.16±3.43 µmol/L, P <0.001) and ALP (-26.8±11.1, -4.56±9.22, -14.48±12.22 and 5.19±2.64 µmol/L, P <0.001) was seen. Variations in DBP and serum NO concentration were not significant. Alpha-tocopherol and symbiotic supplementation among patients with NAFLD resulted in decreased SBP, serum MDA, TNFα levels and enzymes liver; however, they did not affect DBP and serum NO concentration.

11.
J Res Med Sci ; 21: 106, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-28250783

RESUMEN

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. Oral administration of symbiotic and Vitamin E has been proposed as an effective treatment in NAFLD patients. This study was carried out to assess the effects of symbiotic and/or Vitamin E supplementation on liver enzymes, leptin, lipid profile, and some parameters of insulin resistance (IR) in NAFLD patients. MATERIALS AND METHODS: We randomly assigned sixty NAFLD adult patients to receive (1) symbiotic twice daily + Vitamin E-like placebo capsule; (2) 400 IU/d Vitamin E + symbiotic-like placebo; (3) symbiotic twice daily + 400 IU/d Vitamin E; and (4) symbiotic-like placebo + Vitamin E-like placebo for 8 weeks. RESULTS: Symbiotic plus Vitamin E supplementation led to a significant decrease in concentrations of liver transaminase (P ≤ 0.05). Mean difference of apolipoprotein A-1 was more significant in symbiotic group compared to control. However, mean difference of apolipoprotein B100/A-1 was only significant in symbiotic group compared to control. At the end of the study, significant differences in total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were seen between the symbiotic plus Vitamin E and control groups (P < 0.001). Furthermore, intake of symbiotic plus Vitamin E supplements led to a significant decrease in concentrations of triglycerides (TG) after the intervention. Significant differences in leptin, fasting blood sugar (FBS), and insulin levels were seen between the symbiotic plus Vitamin E and control groups at the end of the study (P < 0.001). In contrast, symbiotic and/or Vitamin E supplementation did not affect high-density lipoprotein cholesterol and homeostasis model assessment for IR levels. CONCLUSION: In our study, symbiotic plus Vitamin E supplementation was the most effective treatment in lowering liver enzymes, leptin, FBS, insulin, TG, TC, and LDL-C among NAFLD patients.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA